RO7234292 (RG6042)

DRUG3 trials

Sponsors

Hoffmann-La Roche

Conditions

Huntington DiseaseHuntington's DiseaseHuntingtons Disease

Phase 1

A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease

CompletedNCT04000594

Hoffmann-La RocheHuntingtons Disease

Start: 2019-09-02End: 2022-01-18Updated: 2024-10-03

Phase 2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)

CompletedNCT03342053

Hoffmann-La RocheHuntington's Disease

Start: 2018-01-02End: 2019-10-08Updated: 2022-03-24

Phase 3

An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies

CompletedNCT03842969

Hoffmann-La RocheHuntington Disease

Start: 2019-04-23End: 2022-03-30Updated: 2023-08-31

Related Papers

A digital motor score for sensitive detection of progression in Huntington’s disease

Brain2025-04-111 citations

Recent advances in RNA-targeting therapy for neurological diseases

Neural Regeneration Research2023-04-103 citations

A Remote Digital Monitoring Platform to Assess Cognitive and Motor Symptoms in Huntington Disease: Cross-sectional Validation Study

Journal of Medical Internet Research2022-06-2832 citations

241 Intrathecal antisense oligonucleotide delivery in HD: experience from RG6042 programme and best practice considerations

Journal of Neurology Neurosurgery & Psychiatry2022-05-27

Intrathecal Drug Delivery of Antisense Oligonucleotides in Huntington’s Disease: Experience of Ionis/Roche RG6042 Development Programme and Best Practice Considerations for Real-World Use (950)

Neurology2020-04-14

J02 A global development program testing RG6042, an anti-sense oligonucleotide, for the treatment of early manifest huntington’s disease (hd)

Clinical Therapeutics2018-09-013 citations

Huntington’s Disease Clinical Trials Corner: August 2018

Journal of Huntington s Disease2018-06-0131 citations

Huntington’s Disease Clinical Trials Corner: February 2018

2018-01-0144 citations